Ultrasensitive next-generation sequencing-based detection of circulating human papillomavirus DNA for cervical cancer recurrence monitoring.

This association remained highly significant but was less evident when restricting these analyses to only include patients with detectable pretreatment ccfHPV DNA (adjusted HR, 13.4; 95% CI, 4.9–36.9; p < .001) (Table S10 and Figure S4) .

also in 132,142 other papers